S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
S&P 500   4,535.39 (-0.02%)
DOW   35,531.59 (-0.22%)
QQQ   375.25 (+0.07%)
AAPL   149.52 (+0.17%)
MSFT   308.18 (+0.25%)
FB   340.34 (-0.13%)
GOOGL   2,837.85 (+0.09%)
TSLA   884.20 (+2.13%)
AMZN   3,429.71 (+0.43%)
NVDA   222.46 (+0.65%)
BABA   178.50 (+0.75%)
NIO   40.18 (+1.01%)
CGC   14.52 (+2.91%)
GE   105.59 (-0.39%)
AMD   117.46 (+0.92%)
MU   68.06 (-0.31%)
T   26.05 (+0.54%)
F   16.63 (+3.68%)
ACB   7.84 (+2.35%)
DIS   171.95 (+0.82%)
PFE   42.59 (-0.49%)
BA   217.82 (+0.76%)
AMC   41.72 (+2.05%)
OTCMKTS:STDAF

STADA Arzneimittel Aktiengesellschaft Stock Forecast, Price & News

$110.42
0.00 (0.00 %)
(As of 10/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$110.42
▼
$110.42
50-Day Range
$110.42
▼
$110.42
52-Week Range
$75.15
▼
$115.00
VolumeN/A
Average Volume180 shs
Market Capitalization$6.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.51
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.


STADA Arzneimittel Aktiengesellschaft logo

About STADA Arzneimittel Aktiengesellschaft

STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the Generics and Branded Products segments. The Generics segment produces and distributes generic drugs. The Branded Products segment sells branded healthcare products and medicines. Its brands include Zoflora, Grippostad, Nizoral, and Shampoo & Ladival. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany.

Headlines

News for STADA
January 17, 2021 |  markets.businessinsider.com
Oncology Biosimilars Market Report 2020-2025: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast
December 4, 2020 |  marketwatch.com
STADA Signs Medical Cannabis Supply Deal With MediPharm Labs
October 8, 2020 |  markets.businessinsider.com
German generic drugmaker warns against EU protectionism
June 22, 2020 |  finance.yahoo.com
Oncology Biosimilars Market Repor: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
May 8, 2020 |  www.marketwatch.com
STADA Arzneimittel FY19 Adj. EBITDA Rises; Organic Sales Growth At 8%
March 12, 2020 |  www.nasdaq.com
Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
September 26, 2019 |  www.marketwatch.com
STADA H1 Net Income Declines, Sales Up 11% - Quick Facts
August 14, 2019 |  markets.businessinsider.com
Private equity comes in from the cold in corporate Germany
August 8, 2019 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:STDAF
Previous Symbol
NASDAQ:STDAF
CUSIP
N/A
CIK
N/A
Web
www.stada.com
Phone
(496) 101-6030
Employees
12,301
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.44 billion
Price / Sales
2.00
Cash Flow
$7.83 per share
Price / Cash Flow
14.11
Book Value
$18.64 per share
Price / Book
5.92

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
2.54
Current Ratio
1.48
Quick Ratio
0.84

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
62,342,000
Market Cap
$6.88 billion
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.77 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












STADA Arzneimittel Aktiengesellschaft (OTCMKTS:STDAF) Frequently Asked Questions

What stocks does MarketBeat like better than STADA Arzneimittel Aktiengesellschaft?

Wall Street analysts have given STADA Arzneimittel Aktiengesellschaft a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but STADA Arzneimittel Aktiengesellschaft wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has STADA Arzneimittel Aktiengesellschaft's stock price been impacted by COVID-19?

STADA Arzneimittel Aktiengesellschaft's stock was trading at $88.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STDAF shares have increased by 24.2% and is now trading at $110.42.
View which stocks have been most impacted by COVID-19.

Who are STADA Arzneimittel Aktiengesellschaft's key executives?

STADA Arzneimittel Aktiengesellschaft's management team includes the following people:
  • Peter Goldschmidt, Chairman-Executive Board
  • Wolfgang Ollig, Chief Financial Officer
  • Miguel Pagan Fernandez, Chief Technical Officer
  • Yann Brun, EVP, Head-Regulatory & Business Development
  • Frank Seiler, Head-Investor Relations Contact

What is STADA Arzneimittel Aktiengesellschaft's stock symbol?

STADA Arzneimittel Aktiengesellschaft trades on the OTCMKTS under the ticker symbol "STDAF."

How do I buy shares of STADA Arzneimittel Aktiengesellschaft?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STADA Arzneimittel Aktiengesellschaft's stock price today?

One share of STDAF stock can currently be purchased for approximately $110.42.

How much money does STADA Arzneimittel Aktiengesellschaft make?

STADA Arzneimittel Aktiengesellschaft has a market capitalization of $6.88 billion and generates $3.44 billion in revenue each year.

How many employees does STADA Arzneimittel Aktiengesellschaft have?

STADA Arzneimittel Aktiengesellschaft employs 12,301 workers across the globe.

What is STADA Arzneimittel Aktiengesellschaft's official website?

The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.com.

Where are STADA Arzneimittel Aktiengesellschaft's headquarters?

STADA Arzneimittel Aktiengesellschaft is headquartered at Stadastrasse 2-18, Bad Vilbel 2M, 61118.

How can I contact STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at (496) 101-6030 or via email at [email protected].


This page was last updated on 10/21/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.